… ProQR Announces Recent Progress and Financial Results for the … & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, chief executive officer of ProQR. “In October we announced that LCA10 patients …
… ProQR to Present at Cowen and Company 40th Annual Health Care … will be accessible from the “Investors” section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Announces Publication in Nature Medicine for Sepofarsen … & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … vision,” said Aniz Girach, MD, Chief Medical Officer of ProQR, “The visual field improvements observed indicate that …
… ProQR to Present at the Leerink Partners 4th Annual Rare … be accessible from the 'Investor Relations' section of ProQR's website ( www.proqr.com ) under 'Events and Presentations'. The …
… ProQR Receives Fast Track Designation from FDA for QR-010 for … faster,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to releasing data for the … in this study include sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for … LEIDEN, the Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development at ProQR. “Now that the study is initiated we expect to dose the …
… ProQRR&D day Highlights Progress on Pipeline and Introduces … RNA Technology Key program features and updates: ProQR to host an R&D day in New York today, June 15, from … the nasal potential difference (NPD) study for QR-010, ProQR’s lead molecule for CF that is studied in two clinical …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome